Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage
pharmaceutical company commercializing potential best in class oncology
and CNS therapeutics, today announced that it will present new
pre-clinical data on its oncology compound RX-3117 during a poster
session at the American Association for Cancer Research (AACR) 103rd
Annual Meeting being held in Chicago, Illinois, March 31 - April 4,
2012, at the McCormick Place Convention Center.
The Company will present data on the metabolism and mechanism of action
of RX-3117 in a poster (abstract #1770) entitled, "Metabolism and
mechanism of action of fluorocyclopentenylcytosine (RX-3117)," on
Monday, April 2, 2012, during the "Experimental and Molecular
Therapeutics 10" poster session from 8:00 am - 12:00 pm EDT in Exhibit
Hall F, Poster Section 28.
In September 2009, Rexahn entered into a commercialization and
development agreement with Teva Pharmaceutical Industries Limited for
RX-3117. Under the agreement, Rexahn is eligible to receive development,
regulatory and sales milestone payments, as well as royalties on net
sales worldwide.
Avadel Pharmaceuticals announces publication of RESTORE data highlighting challenges with twice-nightly oxybates and strong patient preference for once-nightly LUMRYZ™ dosing (sodium oxybate) extended-release oral suspension (CIII)